Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 3,919 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02849990
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Degarelix, Indomethacin, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Prostate Cancer

NCT01434290
View directory record Official record
Conditions
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
Interventions
36.25 Gy IMRT, 51.6 Gy IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Nov 13, 2026, 9:32 AM EST
Terminated Phase 1 Interventional

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

NCT05999968
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Springdale, Arkansas • Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Completed Not applicable Interventional

Patient Preference Survey for Radiation Oncologists

NCT00595218
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer
Interventions
Physician behavior related to Patient Preference Survey, Patient Preference Results
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Nov 13, 2026, 9:32 AM EST
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT03431350
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
19
States / cities
Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Nov 13, 2026, 9:32 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin for Rising PSA Remote Trial

NCT02376166
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Nov 13, 2026, 9:32 AM EST
Active, not recruiting Phase 3 Interventional Results available

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Not yet recruiting Not applicable Interventional

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

NCT06811454
View directory record Official record
Conditions
Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage III Colorectal Cancer, Stage II Colorectal Cancer, Stage I Colorectal Cancer
Interventions
MINDSET, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Terminated Phase 2 Interventional

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions
YM598
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 2 Interventional

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00072722
View directory record Official record
Conditions
Prostate Cancer
Interventions
CC-4047
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Nov 13, 2026, 9:32 AM EST
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Active, not recruiting Early Phase 1 Interventional

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

NCT03392181
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Nov 13, 2026, 9:32 AM EST
Terminated Phase 1 Interventional Results available

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

NCT02995330
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bone marrow transplantation, Cytoxan, testosterone cypionate
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 13, 2026, 9:32 AM EST
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 2 Interventional Results available

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Nov 13, 2026, 9:32 AM EST
Not yet recruiting Phase 2 Interventional

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07608718
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Completed Not applicable Interventional

Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer

NCT02342626
View directory record Official record
Conditions
Adenocarcinoma of Prostate
Interventions
Dashboard
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Nov 13, 2026, 9:32 AM EST
Completed Phase 1Phase 2 Interventional Results available

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

NCT03949517
View directory record Official record
Conditions
Prostate Cancer
Interventions
68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan, PET/MRI
Drug · Device · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 13, 2026, 9:32 AM EST
Completed No phase listed Observational

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03707574
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
143
States / cities
Fort Lauderdale, Florida • Savannah, Georgia • Honolulu, Hawaii + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 13, 2026, 9:32 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate

NCT01588938
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research Acquisition Activity
Federal
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Nov 13, 2026, 9:32 AM EST
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 13, 2026, 9:32 AM EST